王建,刘晓红,陈若诗,肖栋

• 1:厦门大学附属心血管病医院心内科
• 2:重庆两江新区第一人民医院心内科
• 3:厦门市长庚医院内科

摘要(Abstract)：

<正>心血管疾病高居城乡居民总死因之首,据统计全球心血管疾病死亡率在过去的20余年里增加了近40%[1]。传统的心脏生物标志物,如肌钙蛋白、脑钠肽、肌酸激酶等在心血管疾病的诊断、危险分层及预后中起着关键作用,血清胱抑素C(cystatin C, CysC)作为一种新型心血管疾病生物标志物,近年来越来越受到关注。本文就Cys C与常规心血管疾病的关系作一综述。

关键词(KeyWords)： 胱抑素C;冠心病;心力衰竭;高血压病

Abstract:

Keywords:

基金项目(Foundation): 福建省卫生计生青年科研课题（2016-2-76）

作者(Author): 王建,刘晓红,陈若诗,肖栋

参考文献(References)：

• [1] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China:current features and implications. Nat Rev Cardiol, 2019, 16(4):203-212.
• [2] Zheng Tan, Li Li, Yi Ma, et al. Clinical significance of Cys-C and hs-CRP in coronary heart disease patients undergoing percutaneous coronary intervention. Braz J Cardiovasc Surg, 2019, 34(1):17-21.
• [3] Mohd Tahir NA, Mohd Saffian S, Islahudin FH, et al. Effects of CST3 Gene G73A Polymorphism on Cystatin C in a Prospective Multiethnic Cohort Study. Nephron,2020,144(4):204-212.
• [4]李恒立，雷建新，郭龙龙.无慢性肾脏疾病病人血清CysC水平与冠心病相关性及其严重性的关系.中西医结合心脑血管病杂志，2019,17(10):1525-1528.
• [5] Huang X, Jiang X, Wang L, et al. Serum cystatin C and arterial stiffness in middle-aged and elderly adults without chronic kidney disease:A population-based study. Med Sci Monit,2019,25:9207-9215.
• [6]李华，支莹，卢彦昭，等.胱抑素C与冠状动脉斑块性质、病变特点的相关性.中华医学杂志，2015,95(1):48-51.
• [7] Shen Y, Ding FH, Zhang RY, et al. Serum cystatin C reflects angiographic coronary collateralization in stable coronary artery disease patients with chronic total occlusion. PLoS One,2015,10(9):e0137253.
• [8] Zhang JJ, Wu XH, Gao PZ, et al. Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome. BMC Cardiovasc Disord, 2017,17(1):47.
• [9] Sugiyama H, Miyoshi T, Osawa K, et al. Serum cystatin C levels are associated with coronary artery calcification in women without chronic kidney disease. J Cardiol, 2017,70(6):559-564.
• [10] Svensson-F?rbom T, Almgren P, Hedblad B, et al. Cystatin C is not causally related to coronary artery disease. PLoS One,2015,10(6):e0129269.
• [11] van der Laan SW, Fall T, SoumaréA, et al. Cystatin C and cardiovascular disease:A mendelian randomization study. J Am Coll Cardiol,2016,68(9):934-945.
• [12] Yang S, Song L, Zhao L, et al. Predictive value of cystatin C in people with suspected or established coronary artery disease:A meta-analysis. Atherosclerosis,2017,263:60-67.
• [13] Zhao CY, Yang LS, Mao LL, et al. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation:results of the 1-year follow-up. Coron Artery Dis,2013, 24(5):357-360.
• [14] Dardashti A, Nozohoor S, Algotsson L, et al. The predictive value of s-cystatin C for mortality after coronary artery bypass surgery. J Thorac Cardiovasc Surg, 2016,152(1):139-146.
• [15] Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019:pharmacotherapy, procedures,devices and patient management. An expert consensus meeting report of the heart failure association of the European Society of Cardiology. Eur J Heart Fail,2019,21(10):1169-1186.
• [16] Dandana A, Gammoudi I, Chalghoum A, et al. Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease. J Clin Lab Anal,2014,28(3):191-197.
• [17] Xu CC, Fu GX, Liu QQ, et al. Association between cystatin C and heart failure with preserved ejection fraction in elderly Chinese patients. Z Gerontol Geriatr,2018,51(1):92-97.
• [18]龚心琰，季亢挺.血清胱抑素C水平与慢性心衰严重程度的相关性研究.中国高等医学教育，2017,(3):132-136.
• [19] Wu X, Xu G, Zhang S. Association between cystatin C and cardiac function and long-term prognosis in patients with chronic heart failure. Med Sci Monit,2020,26:e919422.
• [20] Ruan ZB, Zhu L, Yin YG, et al. Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up:Insights into the cardiorenal syndrome. J Res Med Sci,2014,19(5):404-409.
• [21] Kim TH, Kim H, Kim IC. The potential of cystatin-C to evaluate the prognosis of acute heart failure:A comparative study. Acute Cardiac Care, 2016,17(4):72-76.
• [22] Yamamoto T, Shimano M, Inden Y, et al. Cystatin C as a predictor of mortality and cardiovascular morbidity after cardiac resynchronization therapy. Circ J,2013,77(11):2751-2756.
• [23] Chatterjee NA, Singh JP, Szymonifka J, et al. Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy:the BIOCRT study. Int J Cardiol,2016,205:43-49.
• [24] Rafouli-Stergiou P, Parissis J, Farmakis D, et al. Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. Int J Cardiol,2015,182:74-76.
• [25]郭靓，赵鑫，强雪芹.不同血压分级原发性高血压患者血清CysC和CTRP9水平的表达及临床意义.临床和实验医学杂志，2019,18(19):2078-2081.
• [26]郭皓，袁勇，郭立，等.原发性高血压病患者动态血压均值、动态脉压、动态脉压指数与血清胱抑素C的相关性研究.中国全科医学，2014,17(1):43-46.
• [27]孟祥冬，李娟.原发性高血压患者脉压与胱抑素C的相关性.心血管康复医学杂志，2015,24(1):24-26.
• [28]冯绍明，龚英峰，裴荣光.血清胱抑素C与早期高血压肾损害的相关性研究.实用临床医药杂志，2013,17(13):121-123.
• [29] Li X, Zhu H, Li P, et al. Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy. J Geriatr Cardiol,2013,10(3):286-290.
• [30] Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society(ERS). Eur Heart J,2020,41(4):543-603.
• [31] Tutar N, Kemik NA, Y?lmaz I, et al. Is Serum Cystatin C a Predictor of Acute Pulmonary Thromboembolism in Patients With Normal Renal Function? Clin Appl Thromb Hemost, 2015,21(6):533-538.
• [32] Fenster BE, Lasalvia L, Schroeder JD, et al. Cystatin C:a potential biomarker for pulmonary arterial hypertension.Respirology,2014,19(4):583-589.
• [33] Blok IM, van Riel AC, Schuuring MJ, et al. The role of cystatin C as a biomarker for prognosis in pulmonary arterial hypertension due to congenital heart disease. Int J Cardiol, 2016, 209:242-247.